StockNews.AI
LIXT
StockNews.AI
6 days

24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy

1. LIXTE approved a treasury policy for cryptocurrency investments up to 25%. 2. New strategy aims to hedge against inflation and enhance liquidity. 3. The move signifies LIXTE's progressive approach to capital management. 4. LIXTE joins other firms adopting cryptocurrencies for strategic growth. 5. CEO emphasizes potential long-term returns from cryptocurrency assets.

6m saved
Insight
Article

FAQ

Why Bullish?

LIXTE's entry into cryptocurrency may attract investor attention and increase market confidence. Similar moves by other companies have led to positive stock reactions historically.

How important is it?

LIXTE's strategic treasury relocation reflects broader corporate trends and could enhance investor interest due to increased visibility.

Why Long Term?

Diversifying into cryptocurrencies can offer long-term gains and stability, aligning with ongoing interest in fintech innovations among investors.

Related Companies

GBTCCOINMSTR
DENVER, Aug. 13, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, reports that LIXTE Biotechnology Holdings (Nasdaq: LIXT), a clinical-stage pharmaceutical company developing breakthrough cancer therapeutics, announced today that its Board of Directors approved a bold new treasury policy to diversify its corporate reserves into cryptocurrency, including Bitcoin and potentially other digital assets. The decision underscores the company’s commitment to strategic capital allocation and long-term shareholder value creation. Under the newly adopted policy, up to 25% of LIXTE’s corporate treasury may be allocated to cryptocurrencies. All digital assets will be securely held with a fully regulated and compliant custodian, and all transactions will conform to applicable financial, legal, and audit standards to ensure transparency, security, and regulatory integrity. “LIXTE’s updated treasury policy is based on our conviction in the long-term potential of cryptocurrency to hedge our existing treasury assets, as well as delivering meaningful returns for shareholders,” commented Geordan Pursglove, Chairman and CEO of LIXTE. Strategic and Financial Rationale The shift comes as a growing number of forward-thinking companies adopt cryptocurrencies as part of a diversified treasury management approach. By introducing Bitcoin and potentially other digital assets into its balance sheet, LIXTE aims to: Hedge against inflation and fiat currency depreciationEnhance liquidity with globally recognized, borderless assetsPosition itself at the forefront of fintech-enabled financial strategyLeverage digital assets as a potential asymmetric upside to complement its biotech growth trajectory This treasury diversification strategy could also provide a more dynamic balance sheet, allowing LIXTE to be more agile in capital deployment while benefiting from long-term appreciation in high-conviction digital assets. A Growing Corporate Trend LIXTE joins a growing list of public companies turning to cryptocurrency as a strategic asset class. These moves have often correlated with increased institutional attention, higher shareholder engagement, and greater visibility within both financial and technology sectors. For smaller-cap growth companies like LIXTE, it also signals operational sophistication and a progressive approach to capital efficiency. Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services. About LIXTE Biotechnology Holdings, Inc. LIXTE is a clinical-stage pharmaceutical company focused on discovering and developing innovative cancer therapies targeting the protein phosphatase 2A (PP2A) pathway, a previously underexplored avenue in cancer treatment. The company’s lead compound, LB-100, is a first-in-class PP2A inhibitor that has demonstrated strong preclinical results and early-stage clinical tolerability. LIXTE is currently advancing proof-of-concept trials in Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma. More information can be found at: www.lixte.com 24/7 MARKET NEWS, INC DisclaimerPlease go to https://247marketnews.com/lixte-biotechnology/ for further LIXT information and 247marketnews.com LIXT disclosure information. CONTACT:24/7 Market NewsEditor@247marketnews.com Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, the popularity and/or competitive success of the Company's acquired football and other sports teams, the Company's ability to attract players and staff for acquired clubs, unsuccessful acquisitions or other strategic transactions, the possibility of a decline in the popularity of football or other sports, the Company's ability to expand its fanbase, sponsors and commercial partners, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

Related News